Recent Updates
Recently added Catalysts

Hemab Therapeutics Holdings, Inc.

COAGFDA catalysts, PDUFA dates & pipeline intelligence
$39.86
▲ +0.71 · +1.81%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full COAG financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $23.0052W HIGH $55.42
Volume
248.31 K
Value Traded
9.77 M
Short % Float
11.46%
Days to Cover
7.3
+1.22%Week
+16.65%1 Month
-17.3%3 Month
+51.56%6 Month
-16.13%5 Year
-16.13%All Time

Cash Data

Unlock COAG cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.86 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
1.43 B
Total Shares
46.71 M
Float Shares
28.85 M
Insiders
38.27%
Institutions
67.33%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data presentation
HMB-003
Severe menstrual bleeding (cynomolgus monkey model)
Pre-clinicalPeptidesEndocrine
Unlock every COAG catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

COAG Catalyst Timeline

Dated clinical, regulatory and corporate events for Hemab Therapeutics Holdings, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Hemab Therapeutics Holdings, Inc.

42Total events
9Upcoming
3Tier-1 (high impact)
2026 to 2029Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
Sutacimig
T3Poster Presentation
Subscribe to view catalyst details
HMB-003

Event history 18

●Quarterly UpdateCorporate
Third quarter 2026 financial results and corporate update
▲Trial InitiationSutacimigTrial
Hemab initiates pivotal Phase 3 SOLARA trial of sutacimig in Glanzmann thrombasthenia
Glanzmann thrombastheniasource ↗
●AbstractSutacimigPresentation
ASH abstracts for sutacimig and HMB-003 now available
congenital factor VII deficiencysource ↗
▲First Patient DosedSutacimigTrial
First clinical data from single ascending dose cohort of Phase 2b sutacimig trial in FVIID
Factor VII deficiencysource ↗
▲Trial InitiationSutacimigTrial
Initiation of SOLARA pivotal Phase 3 trial of sutacimig in Glanzmann thrombasthenia
Glanzmann thrombastheniasource ↗
●Management ChangeCorporate
Keli Walbert appointed to Hemab Board of Directors
▲First Patient DosedHMB-003Trial
First participant dosed in Phase 1 trial of HMB-003
Heavy menstrual bleedingsource ↗
▲First Patient DosedHMB-003Trial
First participant dosed in Phase 1 trial of HMB-003 in heavy menstrual bleeding
heavy menstrual bleedingsource ↗
●Management ChangeCorporate
Keli Walbert appointed to Board of Directors
▲Oral PresentationHMB-002Presentation
Oral presentation of HMB-002 data at ISTH 2026
Unlock the full COAG catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How COAG actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-07-14Sutacimig (HMB-001) Phase 2 data readout Phase 2
Unlock 3 more COAG historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 34%
Micro Cap
(rank 246 of 723)
Percentile Rank
Showing 5 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
HMB-002 BiologicsNCT06754852Von Willebrand Disease (VWD)Phase 1/2 RECRUITING 108Jul 1, 2027
HMB-003 PeptidesNCT07798505UndisclosedPhase 1 RECRUITING 40Apr 30, 2027
Sutacimig BiologicsNCT07935356ThrombastheniaPhase 3 RECRUITING 76Jan 1, 2030
Sutacimig BiologicsNCT06211634Glanzmann ThrombastheniaPhase 1/2 ACTIVE NOT_RECRUITING 57Aug 1, 2027
Sutacimig BiologicsNCT07347249Congenital Factor VII DeficiencyPhase 2 RECRUITING 18Nov 1, 2027
Unlock the COAG pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every COAG program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
sutacimig
BreakthroughFast TrackOrphan
Factor VII deficiencyPhase 2b2026-11-04prothrombin time shortening: more than 50%; endogenous FVIIa accumulation: ~5x; exposure duration: through Day 22Read MoreHemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and ExpositionRead More
Scroll for more · summaries link to the source press release
Unlock every COAG trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock COAG insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
RA CAPITAL MANAGEMENT, L.P.10% OwnerBuy 61,523 6,444,637 held$24.98 06/16/2026
Unlock the full COAG insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
RA CAPITAL MANAGEMENT, L.P. 2.4 % (-4 %) 240.82 M 7.81 M
Unlock every fund holding COAG
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in COAG
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see COAG ownership
Insider and institutional ownership, quarter by quarter.

COAG Short Interest

Shares sold short, counted twice a month.

11.46%
Short % of Float
of tradable shares sold short
3.3M
Shares Sold Short
+4.6% vs prior count
7.3 High
Days to Cover
trading days of normal volume to buy every short share back
452.0K
Avg Daily Volume
the average used for days to cover
Unlock COAG short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock COAG option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live COAG option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock COAG options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How COAG ranks across every disease it competes in

Competitive Position is a premium feature
See how COAG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

COAG News

COAG
Nov 11, 2026
COAGConferences/Events

Hemab Therapeutics to Participate in Upcoming Investor Conferences

Hemab Therapeutics announced participation in two upcoming investor conferences. The 2026 Jefferies Global Healthcare Conference will take place on November 17, followed by the 9th Annual Evercore Healthcare Conference on December 1. The management team will host investor meetings and provide a live webcast of their presentations.

Read more →
COAG
Nov 10, 2026
COAGPhases
▼ -9.4%on this newsshared move

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics reported positive developments in its clinical programs, including the initiation of a Phase 3 trial for sutacimig in Glanzmann thrombasthenia and the first participant dosed in a Phase 1 trial for HMB-003 targeting heavy menstrual bleeding. The company also announced promising early data for sutacimig in Factor VII deficiency. Financial results showed a net loss of $27.3 million for Q3 2026.

Read more →
COAG
Nov 9, 2026
COAGPhases
▼ -12.7%on this newsshared move

Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia

Hemab Therapeutics has launched the SOLARA trial to evaluate sutacimig for Glanzmann thrombasthenia. This pivotal Phase 3 trial will involve approximately 75 participants and aims to reduce bleeding events. The primary endpoint is the annualized treated bleed rate. The trial follows promising Phase 2 results, although some safety concerns were noted.

Read more →
COAG
Nov 4, 2026
COAGConferences/Events

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

Hemab Therapeutics announced the presentation of clinical and preclinical data at the 68th ASH Annual Meeting. Initial results for sutacimig in Factor VII deficiency show significant accumulation of endogenous FVII(a) and reduced prothrombin time. Additionally, preclinical data for HMB-003 indicate its potential to reduce severe menstrual bleeding. Both therapies aim to address critical gaps in coagulation treatment.

Read more →
COAG
Nov 3, 2026
COAGConferences/Events

Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026

Hemab Therapeutics will host a conference call on November 10, 2026, at 8:00 a.m. ET to discuss its third-quarter financial results and provide a corporate update. The company focuses on developing therapies for blood coagulation disorders, with several innovative treatments in clinical development. A replay of the call will be available for 90 days post-event.

Read more →
COAG
Sep 24, 2026
COAGGeneral

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

Hemab Therapeutics has appointed Keli Walbert to its Board of Directors, effective September 24, 2026. Walbert, who brings over 20 years of commercial leadership experience, will join the Audit Committee and replace Akshay Vaishnaw. Her background in launching therapies for various diseases is expected to strengthen Hemab's efforts in developing treatments for bleeding disorders.

Read more →
COAG
Sep 17, 2026
COAGPhases

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

Hemab Therapeutics has initiated a Phase 1 clinical trial for HMB-003, a novel therapy aimed at managing heavy menstrual bleeding. This investigational treatment, designed to inhibit plasmin and stabilize blood clots, has shown promising results in preclinical studies. The trial aims to evaluate its safety and pharmacokinetics, with results expected by mid-2027.

Read more →
COAG
Aug 11, 2026
COAGGeneral

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics reported second quarter 2026 financial results and provided a corporate update. The FDA endorsed sutacimig data for a Phase 3 trial in Glanzmann thrombasthenia, with initiation planned for the second half of 2026. New data for HMB-002 showed a 2.4-fold increase in Von Willebrand Factor and Factor VIII levels. The company also unveiled HMB-003, a new plasmin inhibitor for heavy menstrual bleeding.

Read more →
COAG
Jul 14, 2026
COAGPhases
▲ +9.6%on this news· ran to +25% by day 3

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Hemab Therapeutics presented promising clinical and preclinical data for sutacimig at the ISTH 2026 Congress, showing significant bleed reduction in patients with Glanzmann thrombasthenia and Factor VII deficiency. The Phase 2 long-term extension data indicated a manageable safety profile and FDA agreement on advancing to Phase 3 trials. Additionally, preclinical findings suggest sutacimig's broad applicability in treating bleeding disorders.

Read more →
COAG
Jul 12, 2026
COAGPhases

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

Hemab Therapeutics presented promising clinical data for HMB-002 in treating Von Willebrand Disease and introduced HMB-003 for heavy menstrual bleeding at the ISTH 2026 Congress. HMB-002 demonstrated significant increases in Von Willebrand Factor and Factor VIII, supporting its potential for monthly dosing. HMB-003 is designed as a non-hormonal antifibrinolytic to address heavy menstrual bleeding, aiming to provide effective treatment options for women.

Read more →
COAG
Jun 26, 2026
COAGConferences/Events
▲ +16.8%on this news· ran to +33% by day 1

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

Hemab Therapeutics announced significant advancements in its blood coagulation programs, including promising first-in-human data for HMB-002 in Von Willebrand disease and the introduction of HMB-003, a new peptide plasmin inhibitor. The company plans to present nine studies at the ISTH 2026 Congress, showcasing its commitment to addressing critical gaps in coagulation disorder treatments. Sutacimig has also received FDA Breakthrough Therapy designation, with a Phase 3 trial expected to begin in the second half of 2026.

Read more →
COAG
May 27, 2026
COAGConferences/Events

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Hemab Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference, where its management team will present and hold investor meetings. The event is scheduled for June 4, 2026, in New York, NY. Hemab is focused on developing therapies for blood coagulation disorders, including treatments for Glanzmann thrombasthenia and Von Willebrand Disease.

Read more →
COAG
May 21, 2026
COAGGeneral

Hemab Therapeutics Reports First Quarter 2026 Financial Results

Hemab Therapeutics has reported its first quarter financial results for 2026, highlighting the successful completion of an initial public offering that raised $346.7 million and secured a listing on Nasdaq. The company received Breakthrough Therapy Designation for sutacimig, a bispecific antibody for Glanzmann thrombasthenia. Despite these advancements, Hemab reported a net loss of $22.687 million in the quarter, with a decrease in cash reserves compared to the previous quarter.

Read more →
COAG
May 4, 2026
COAGGeneral

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Hemab Therapeutics Holdings, Inc. has successfully closed its upsized initial public offering, selling 19,262,500 shares at $18.00 each. The offering generated approximately $346.7 million in gross proceeds. The company's stock began trading on the Nasdaq Global Select Market under the ticker COAG. The underwriters fully exercised their option to purchase additional shares.

Read more →
COAG
May 1, 2026
COAGGeneral

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

Hemab Therapeutics Holdings, Inc. has announced the pricing of its initial public offering, offering 16,750,000 shares at $18.00 each. The IPO is expected to generate around $301.5 million in gross proceeds. Trading is set to begin on the Nasdaq Global Select Market under the ticker 'COAG' on May 1, 2026, with the offering closing around May 4, 2026.

Read more →

About Hemab Therapeutics Holdings, Inc.

Cambridge, MA hemab.com
Headquarters101 MAIN STREET, CAMBRIDGE, MA, 02142
Founded2020
BIOPHARMAWATCH ELITE
Trade the next COAG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime